A wild ride for TransThera investors: what’s the story?
The firm’s core drug has passed a minor clinical milestone, but the rally really took off when the stock was included in an array of indices tracked by passive funds…
TransThera seeks Hong Kong IPO to sustain cancer drug research
The developer of drugs for advanced or recurrent cancers has already conducted nine financing rounds, but will not start generating commercial revenue before 2026, as all its products are still…
